| Bioactivity | PI-273 is a first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM. PI-273 can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis[1]. | ||||||||||||
| Invitro | PI-273 (2 μM; 48 hours) blocks the cell cycle at the G2-M phase[1]. PI-273 (2 μM; 48 hours) induces cell apoptosis in all three Ras wild-type breast cancer cells: MCF-7, T-47D, and SK-BR-3[1]. PI-273 (0.5-2 μM; for 3 days) can suppress the AKT signaling pathway in a dose- and time-dependent manner[1]. PI-273 of 1 μM and 2 μM inhibits the cell proliferation of both MCF-7 and T-47D cells in a time-dependent manner[1]. Cell Cycle Analysis[1] Cell Line: | ||||||||||||
| Name | PI-273 | ||||||||||||
| CAS | 925069-34-7 | ||||||||||||
| Formula | C16H16ClN3O2S2 | ||||||||||||
| Molar Mass | 381.90 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|